Clinical trial
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By…
NCT00436605 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00436605 |
|---|---|
| Title | Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma |
| Official title | A Phase 2 Study of Dasatinib in Advanced Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma |
| Intervention type | Drug |
| Interventions | dasatinib |
| Enrollment | 39 |
| Start date | Dec 1, 2006 |
| Primary completion | Mar 1, 2010 |
| Completion | Nov 1, 2010 |
| First posted | Feb 19, 2007 |
| Last update posted | May 15, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: